On Tuesday, Viridian Therapeutics Inc (NASDAQ: VRDN) was -0.67% drop from the session before settling in for the closing price of $17.98. A 52-week range for VRDN has been $11.40 – $27.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -4.19% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 23.77%. With a float of $70.18 million, this company’s outstanding shares have now reached $79.18 million.
In an organization with 96 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -2047.68%, operating margin of -93722.52%, and the pretax margin is -85127.15%.
Viridian Therapeutics Inc (VRDN) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Viridian Therapeutics Inc stocks. The insider ownership of Viridian Therapeutics Inc is 11.40%, while institutional ownership is 100.99%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 23.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.47% during the next five years compared to 20.35% growth over the previous five years of trading.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
You can see what Viridian Therapeutics Inc (VRDN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 18.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4715.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.31, a number that is poised to hit -1.04 in the next quarter and is forecasted to reach -4.16 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Let’s dig in a bit further. During the last 5-days, its volume was 1.15 million. That was inferior than the volume of 1.19 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.82%. Additionally, its Average True Range was 1.04.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 11.89%, which indicates a significant decrease from 23.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.73% in the past 14 days, which was lower than the 61.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.21, while its 200-day Moving Average is $17.67. However, in the short run, Viridian Therapeutics Inc’s stock first resistance to watch stands at $18.32. Second resistance stands at $18.78. The third major resistance level sits at $19.41. If the price goes on to break the first support level at $17.23, it is likely to go to the next support level at $16.60. The third support level lies at $16.14 if the price breaches the second support level.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
There are 79,213K outstanding shares of the company, which has a market capitalization of 1.41 billion. As of now, sales total 310 K while income totals -237,730 K. Its latest quarter income was 90 K while its last quarter net income were -76,690 K.
